Role of RHOB in the antiproliferative effect of glucocorticoid receptor on macrophage RAW264.7 cells

Xiaohui Wang*, Yuxia Chen*, Yan Wang, Xiaoyan Zhu, Yuanyuan Ma, Shimin Zhang¹ and Jian Lu

Department of Pathophysiology, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People's Republic of China
¹American Registry of Pathology at Armed Forces Institute of Pathology, Washington, District of Columbia 20007, USA

(Correspondence should be addressed to J Lu; Email: lujian326@163.com)

*(X Wang and Y Chen are co-first-authors)

Abstract

Although glucocorticoid (GC) has been reported to inhibit macrophage killing activity and cytokine production in response to proinflammatory stimuli, the effect of GC on macrophage proliferation is controversial. In our previous study, we found that inhibition of glucocorticoid receptor (GR) expression in murine macrophage cell line RAW264.7 cells (RAW-GR(−) cells) by RNAi significantly promoted cell proliferation. In the present study, we provide the evidence that the expression of Rhob, a member of Rho GTPases with anti-cancer character, remarkably decreased in RAW-GR(−) and RAW264.7 cells transiently transfected with GR-RNAi vector. Overexpression or constitutive activation of Rhob in RAW-GR(−) and RAW264.7 cells by transfection with wild-type Rhob expression vector (Rhob-wt) or constitutively activated Rhob plasmid (Rhob-V14) resulted in decreased proliferation of the two cell lines. Oppositely, the proliferation of RAW264.7 cells was significantly increased when the expression of Rhob by RNA interference technique or the activity of Rhob by transfection with dominant negative Rhob mutant that is defective in nucleotide binding (Rhob-N19) was inhibited. In addition, enhanced activity of Akt, but not MAPK3/1 or MAPK14, was found in RAW-GR(−) cells. Blocking the pathway of phosphatidylinositol 3-kinase (PI3K)/Akt with the specific inhibitor LY294002 decreased the proliferation and elevated RHOB protein level, indicating that PI3K/Akt signal plays its role of proliferation modulation upstream of RHOB protein. In conclusion, these results demonstrate that Rhob plays an important role in the antiproliferative effect of GR on RAW264.7 cells by GR→Akt→Rhob signaling and Rhob negatively regulates the proliferation of RAW264.7 cells.

Journal of Endocrinology (2009) 200, 35–43

Introduction

Glucocorticoid (GC) is a significant hormone in regulating diverse physiological processes such as immune and inflammatory responses, cell proliferation, differentiation, and apoptosis (Dondi et al. 2001, Kudawara et al. 2001, Distelhorst 2002, Yamamoto et al. 2002). The common use of GC in treating inflammatory and autoimmune diseases is mostly due to its function of immunosuppression, for instance, inhibition of growth and induced apoptosis in lymphocytes, and repression of cytokine production in macrophages (Distelhorst 2002, Frankfurt & Rosen 2004). Macrophages also play a key role in the immune and inflammatory process, mainly acting as antigen-processing/presenting cells and sources of inflammatory cytokines. Although GC has been reported to suppress macrophage killing activity and cytokine production in response to proinflammatory stimuli (Brummer et al. 2005), the effect of GC on macrophage proliferation is controversial (Lloberas et al. 1998, Sakai et al. 1999, Pagniello et al. 2002).

It is well known that the action of GC was mediated by glucocorticoid receptor (GR) that belongs to nuclear receptor superfamily and is normally localized in the cytoplasm in an inactive state. On hormone binding, GR translocates to the nucleus where it binds to glucocorticoid response elements (GREs) on target genes, recruits coactivators, or corepressors to regulate the expression of target genes (Heitzer et al. 2007). But a few target genes have been known to mediate the antiproliferative effect of GC until now. Rhob is a member of Rho GTPase family and has a tumor-suppressive role, including inhibiting cell proliferation and inducing apoptosis in several human cancer cells, and inhibiting tumor growth in a nude mouse xenograft model (Prendergast 2001, Mazieres et al. 2004). Rhob expression level has recently been shown to dramatically decrease in several cancer cells and patient biopsies such as lung cancer, brain cancer, neck and head tumors as tumors become more aggressive, and ectopic expression of Rhob antagonizes oncogene-mediated transformation (Liu et al. 2001, Adnane et al. 2002, Forget et al. 2002, Jiang et al. 2004a,b, Mazieres et al. 2004, Huang & Prendergast 2006). Recently, we found that GC/GR increased Rhob expression in several tumor cells, such as human ovarian cancer cell lines HO-8910 and 3AO, as well as human hepatocellular carcinoma cell.
SMMC-7721, and the proliferation inhibition of GC/GR on HO-8910 cells is partly due to the increased expression of Rhob (Chen et al. 2006). Although Rhob activation was required for mannose receptor-mediated phagocytosis of human alveolar macrophages (Zhang et al. 2005), the role of Rhob in the proliferation of macrophage was unclear until now.

In our previous study, we found that Dex inhibited the growth of RAW264.7 cells, a murine macrophage cell line. Treatment of RAW264.7 cells with $10^{-7}$ M Dex for 4 days resulted in about 27% inhibition of cell proliferation. We also found unexpectedly that inhibition of GR expression in RAW264.7 by RNA interference significantly promoted cell proliferation. The cell number of RAW-GR(−) cells (stably transfected with GR RNA interference plasmid) was almost twofold as that of the RAW-control cells (stably transfected with RNA interference control plasmid) after 4-day culture (Zhu et al. 2004). These results indicated that GC/GR negatively regulated the growth of RAW264.7 cell, and compared with GC, the expression of functional GR seemed to be more important in keeping cells a more differentiated and less proliferative phenotype. This prompted us to further clarify the molecular mechanism responsible for the antiproliferative effect of GR on RAW264.7 cells. In this study, we investigated the expression of Rhob in RAW-GR(−) cells and its possible role in GC/GR-mediated proliferation inhibition of RAW264.7 cells.

Materials and Methods

Materials

Materials used in the present study included mouse monoclonal antibodies against β-actin and 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl-2H-tetrazolium bromide (MTT; Sigma–Aldrich Chemicals); rabbit polyclonal antibodies against GR and Rhob (Santa Cruz Biotechnology, Santa Cruz, CA, USA); goat anti-rabbit-AP and goat anti-mouse–AP conjugate (Bio-Rad Laboratories); RPMI 1640 medium (Life Technologies Inc.); RNA interfering expression vector pSilencer 2.1-U6 and negative control plasmid (Ambion, Austin, TX, USA); and BCA protein assay kit (Pierce, Pierce, IL, USA).

The wild-type Rhob expression vector (pcDNA3–Rhob; named Rhob-wt), constitutively active Rhob mutant containing a point mutation in the GTPase domain (G14V; named Rhob-V14), and dominant negative Rhob mutant that is defective in nucleotide binding (T19N; named Rhob-N19) were generously provided by Dr Prendergast (2001).

Cell lines and cell culture

Murine macrophage cell line RAW264.7 was obtained from American Type Culture Collection (Rockville, MD, USA). RAW-GR(−) and RAW-control cells were established by stable transfection of RAW264.7 cells with GR-siRNA expression vector and siRNA control vector respectively (Zhu et al. 2004). All the cells were cultured in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum at 37 °C in a humidified incubator of 5% CO₂.

Quantitative real-time PCR

Total RNA was extracted with the TRIzol reagent and 2 μg total RNA was used to synthesize first-strand cDNA by reverse transcription system (Promega), in accordance with the manufacturer's instructions.

Primers for amplification of Rhob gene were sense: 5′-CTG GCC CGC ATG CA-3′ and antisense: 5′-AGG CAG TCT GGT GGT GTC C-3′ (186 bp), and those for β-actin were sense: 5′-CTG TAT GCC TCT GGT AC-3′ and antisense: 5′-TGA TGT CAC GCA CGA TTT CC-3′ (214 bp). SYBR Green from OPEN company was used as the fluorescence reagent. cDNA template (100 and 50 ng for the amplification of Rhob and β-actin respectively) was added to the mixture of 2 μl 10X buffer, 1-6 μl of 25 mM MgCl₂, 0.5 μl of 20 mM dNTP, 0.3 μl of 20 mM primers, 1.5 U Taq enzyme, and 1.0 μl of 20X SYBR. Green to a final volume of 20 μl. Amplification of Rhob and β-actin was performed in different tubes, with the same process: denaturation at 94 °C for 15 s, annealing at 57 °C for 20 s, elongation at 72 °C for 15 s for 36 cycles, and a final extension for 10 min at 72 °C.

The mRNA ratio of Rhob and actin was calculated as follows: we first drew the standard curves of Rhob and β-actin by measuring the threshold cycles (CT) of standards of different concentrations, which had strong positive relationship with the start copy number (i.e. cDNA amounts) of a gene in linear amplification period. Then the cDNA amounts of Rhob and β-actin of each testing sample were calculated according to their standard curves, and cDNA amount of Rhob was normalized by the corresponding β-actin.

Western blot analysis

Whole cell extract was prepared with lysis buffer (Stamatakis et al. 2002; 10 mM Tris (pH 7.5), 0·1 mM EDTA, 0·1 mM EGTA, 0·5% SDS, 0·1 mM mercaptoethanol, 2 μg/ml of each of the protease inhibitors leupeptin, aprotinin, and pepstatin). The lysate was briefly sonicated on ice, and spun at 14 000 r.p.m./min for 10 min to remove the insoluble material. Protein concentrations of the supernatant were measured with BCA protein assay kit. Twenty to fifty micrograms of extracts were resolved on 10% SDS–PAGE gel. After electrophoresis, the proteins were electrotransferred to a nitrocellulose membrane, which were then blocked with 5% nonfat milk and probed overnight with antibodies against Rhob (1:200), GR (1:1000), total and phosphorylated MAPK3/1, MAPK14, phosphorylated Akt (1:500), or β-actin (1:10 000). Then the membranes were washed, exposed to alkaline phosphatase (AP)-conjugated secondary antibodies for 2 h, and finally detected by NBT/BCIP staining. The quantitativeness of protein expression was made by Tanon Bio-image software (Shanghai, China).
RNA interference constructs for Rhob and transfection

Using online siRNA sequence selector tool (BD Clontech), siRNA templates were designed to match nonconserved 19 nucleotide sequences within the mouse Rhob mRNA. The sequences of the oligonucleotides used to create Rhob-RNAi were: 1) sense: 5'-GAT CCC GCC TAT GAC TAC CTC GAG TTT CAA GAG AAC TCG AGG TAG TCA TAG GCT TTT TGG GAA A-3' and antisense: 3'-GCC GGA TAC TGA TGG AGC TCA AAG TTT TCT TCT TGA GCT CCA TCA GTA TCC GAA AAA A CC TTT TCG A-5', and 2) sense: 5'-GAT CCC GGC CTA CGG ATC CCA GAA TTT CAA GAG AAT TCT GGG ATC CGT AGG GCT TTT TGG GAA A-3' and antisense: 3'-GCC GGG ATG CCT AGG GTC TTA AAG TTC TCT TAA GAC CCT AGG CAT CGC GAA AAA ACC TTT TCG A-5'.

Negative control plasmid was supplied from Ambion; it expressed a hairpin siRNA with limited homology to any known sequences in the human, mouse, and rat genomes. The oligonucleotides were synthesized by Sangon Technology Inc. (Shanghai, China) and were annealed/cloned into pSilencer 2.1-U6 vectors. The clones were confirmed by DNA sequencing. Expression of siRNA for Rhob is under control of the U6 promoter.

pSilencer 2.1-U6–Rhob or pSilencer 2.1-U6 control plasmid was introduced into RAW264.7 cells with LipofectAMINE Plus reagent (Invitrogen). Briefly, the cells were transfected with 3 μg DNA in each well of a 6-well plate, according to the manufacturer's instructions.

Transfected of the cells

Cells were seeded onto 24-well plates (4 × 10^4 cells/well) or 6-well plates (2 × 10^5 cells/well) for 24 h and then transiently transfected with 1 (for 24-well plate) or 3 μg (for 6-well plate) of the blank vector (pcDNA3), Rhob-wt, Rhob-V14, Rhob-RNAi, or Rhob-N19 plasmid using LipofectAMINE Plus reagent (Invitrogen), according to the manufacturer's instructions.

Cell proliferation assay

Twenty-four hours after transfection with various Rhob plasmid as indicated above, cells were rinsed out and seeded in duplicate at 3 × 10^4 cells per well onto 24-well plate for MTT assay or 2 × 10^5 cells per well onto 6-well plate for cytometry. After incubation for 2 days, the cell number in each well was collected and counted with a hemacytometer or examined by MTT assay. Two hundred microliters of RPMI 1640 medium containing 5 mg/ml MTT (Sigma–Aldrich Chemicals) solution were added to each well. The cells were incubated for another 4 h at 37°C, followed by solubilization with 200 μl DMSO solutions. Then the O.D. value was measured using a Bio-Rad (model 550) microplate reader at 550 nm with the DMSO as blank.

Statistical analysis

Data are expressed as X±S.D. Statistical significance was determined by Student's t-test with P<0.05 considered as statistically significant.

Results

Inhibition of GR expression in RAW264.7 cells by stable or transient transfection with GR RNA interference vector decreased Rhob expression of the cells

Considering that Rhob showed a proliferation inhibitory effect on several tumor cells, and the proliferation of RAW-GR(-) cells (stably transfected with GR-RNAi vector) increased after inhibition of GR expression, we examined the expression of Rhob at mRNA and protein levels in RAW-GR(-) cells by quantitative real-time PCR (Fig. 1A) and western blot analysis (Fig. 1B) respectively. As expected, the mRNA and protein levels of Rhob in RAW-GR(-) cells were reduced to about 22% and 28% of RAW-control cells respectively.

RAW-GR(-) cells were originated from a single clone. Several single clones of RAW-GR(-) cells were established and down-regulation of Rhob expression was also found in other clones (data not shown). To validate down-regulation of Rhob expression induced by a decreased level of GR, RAW264.7 cells were transient transfected with GR-RNAi vector and the protein level of Rhob was decreased in RAW264.7 cells (Fig. 1C), which indicated that down-regulation of Rhob expression in RAW264.7 cells stably or transiently transfected with GR-RNAi vector was indeed a result from the knock down of GR.

Decreased expression of Rhob is involved in the increased proliferation of RAW-GR(-) cell

As increased proliferation was in concurrence with significantly decreased expression of Rhob in RAW-GR(-) cells, we hypothesized that decreased expression of Rhob might be related to the growth acceleration of RAW-GR(-) cells. To evaluate this possibility, we transfected RAW-GR(-) cells with Rhob-wt (Rhob wild-type construct) Rhob-V14 (a constitutively active Rhob plasmid) or blank vector to detect the effect of Rhob on the cell proliferation by MTT assay and cytometry. As shown in Fig. 2A, the protein level of Rhob increased about twofold in RAW-GR(-) cells transfected with Rhob-wt plasmid. The increase in expression and activation
of Rhob in RAW-GR(−) cells resulted in about 27 and 34% decrease in cell proliferation respectively (Fig. 2B). Similar results were obtained by cytometry (Fig. 2C). These data indicated that decreased expression of Rhob is involved in the increased proliferation of RAW-GR(−) cell.

**GC/GR induces the expression of Rhob at mRNA and protein levels in RAW264.7 cells**

Recently, we found that GC/GR increased Rhob expression in human ovarian cancer cell lines HO-8910 and 3AO, as well as human hepatocellular carcinoma cell SMMC-7721, and the proliferation inhibition of GC/GR on HO-8910 cells is partly due to the increased expression of Rhob (Chen et al. 2006). To determine the effect of GC on the expression of Rhob in RAW264.7 cells, we investigated the mRNA and protein levels of Rhob in the cells treated with $10^{-7}$ M Dex for different times by quantitative real-time PCR, and western blot respectively. Figure 3A shows that Dex induced the mRNA expression of Rhob in a time-dependent manner, with the maximal effect at 2 h after treatment with $10^{-7}$ M Dex. A significant increase in RHOB protein expression was also observed following incubation of cells with $10^{-7}$ M Dex for 4 h. Furthermore, RU486, anti-agonist of GR, could partially attenuate the up-regulation of Rhob by Dex, indicating that activation of GR is required for Rhob induction (Fig. 3B).

**Rhob negatively regulates the proliferation of parental RAW264.7 cells**

To examine whether Rhob has a direct inhibition effect on the proliferation of parental RAW264.7 cells, we used RNAi (RNA interference) to knock down endogenous Rhob expression in this cell line. The results of western blot showed that both the two Rhob–RNAi plasmids obviously reduced the expression of Rhob in RAW264.7 cells by about 73% [Rhob–RNAi(1)] and 88% [Rhob–RNAi(2)], when compared with that of control siRNA plasmid (Fig. 4).

The proliferation of RAW264.7 cells was detected by MTT and cytometry after transient transfection with blank vector, Rhob–RNAi(2), Rhob–N19 (dominant negative mutant plasmid), Rhob–wt, or Rhob–V14. As shown in Fig. 5A, inhibition of the expression and the activity of Rhob by transfection with Rhob–RNAi and Rhob–N19 resulted in about 44 and 36% increase in the cell number respectively, compared with that of the blank vector control (pcDNA3 or RNAi-control) cells. Rhob overexpression or constitutive activation of Rhob by transfection of RAW264.7 cells with Rhob–wt or Rhob–V14 decreased the cell number to about 80 and 62% of the blank cell number.

---

**Figure 1** Inhibition of GR expression in RAW264.7 cells by stable or transient transfection with GR RNA interference vector decreased Rhob expression of the cells. (A) Rhob mRNA level in RAW-GR(−) and RAW-control cells (stably transfected with GR-RNAi vector and RNAi control vector respectively) was detected by quantitative real-time PCR ($X \pm S.D., n = 3$). **$P < 0.01$** versus RAW-control. (B) The protein level of RHOB in the two cells was assayed by western blot analysis. Similar results were obtained from three independent experiments. Using Tanon software (Shanghai China), the blots of Rhob in these two cells were quantified and normalized against β-actin. The normalized numbers from three independent experiments were compared. The values are expressed as the percentage of the level of RAW-control, as shown in the bar graph of B ($X \pm S.D., n = 3$). **$P < 0.01$** versus RAW-control. (C) The protein level of RHOB in RAW264.7 cells transiently transfected with GR-RNAi vector or RNAi control vector was assayed by western blot analysis. Similar results were obtained from three independent experiments.
vector control cells. Similar results were obtained by MTT assay (Fig. 5B). These results further demonstrated that Rhob signaling negatively regulated the proliferation of RAW264.7 cells.

Akt phosphorylation, but not MAPK3/1 and MAPK14, is involved in the accelerating the growth of RAW-GR(−) cells

In recent years, evidence has emerged that GR plays important roles in regulating cell proliferation by modulating the activity of Akt (Leis et al. 2004, Chrysis et al. 2005, Nuutinen et al. 2006), MAPK3/1 and MAPK14 (Miller et al. 2005, Qin et al. 2005), so we examined the activated status of these kinases in RAW-GR(−) and RAW264.7 cells by western blot. We failed to find a significant difference in phosphorylated MAPK3/1 or MAPK14 level between RAW-GR(−) and RAW-control cells (data not shown), but found about a 79% increase in phosphorylated Akt in RAW-GR(−) cells compared with that of RAW-control cells (Fig. 6A). To validate the effect of Akt on the increased proliferation of RAW-GR(−) cells, we further examined the effect of LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K)/Akt pathway, on cell growth by

Figure 2 Transfection of RAW-GR(−) cells with Rhob wild-type plasmid or constitutively active Rhob plasmid inhibits cell proliferation. (A) The protein level of RHOB in RAW-GR(−) cells was assayed by western blot analysis. Similar results were obtained from three independent experiments. RAW-GR(−) cells were transfected with blank vector, Rhob-wt (wild-type Rhob cDNA), or Rhob-V14 (constitutively active Rhob mutant) for 24 h, and then seeded and cultured in duplicate for 2 days onto 24-well plate (3 × 10⁴ cells/well) for (B) MTT assay or (C) 6-well plate (2 × 10⁵ cells/well) for cytometry (X ± s.d.). *P<0.05 versus cells transfected with blank vector. n=3.

Figure 3 Dex increases Rhob expression at mRNA and protein levels in RAW264.7 cells. (A) Rhob mRNA expression in RAW264.7 cells after treatment with 10⁻⁷ M concentrations of Dex for different times was examined by real-time PCR. Dex induced the mRNA expression of Rhob in a time-dependent manner, with the maximal effect at 2 h after treatment with 10⁻⁷ M Dex (X ± s.d., n=3). **P<0.01 versus control. (B) Protein level of RHOB in RAW264.7 cells treated with 10⁻⁷ M Dex with or without 10⁻⁶ M RU486 was examined by western blot analysis. Similar results were obtained from three independent experiments. The blots of Rhob were quantified by Tanon software and normalized against β-actin. Then the normalized numbers from three independent experiments were compared. The values are expressed as fold of the level of control, as shown in the bar graph of (B) (X ± s.d., n=3). **P<0.01 versus control.

www.endocrinology-journals.org

Downloaded from Bioscientifica.com at 07/29/2019 06:52:41AM via free access
MTT assay. As shown in Fig. 6B, treatment of cells with 25 μM LY294002 resulted in a more obvious growth repression in RAW-GR(K) cells than that in RAW-control cells, though the effect could be seen in both the two cells. These results indicated that enhanced activity of Akt, but not MAPK3/1 and MAPK14, was also associated with the increased proliferation of RAW-GR(K) cells.

Blocking PI3K/Akt pathway in RAW-GR(−) and RAW264.7 cells by LY294002 and inhibiting Akt activity in RAW264.7 cells by Dex-increased Rhob expression of the cells

Given that both PI3K/Akt and Rhob are involved in the growth of RAW-GR(−) cells, the relevance between the two signaling pathways was then investigated. RAW-GR(−) cells and its parental RAW264.7 cells were treated with 0–50 μM LY294002 for 12 h, and the expression of Rhob mRNA was then detected by real-time PCR. As shown in Fig. 7A, the expression of Rhob mRNA in RAW-GR(−) and RAW264.7 cells increased gradually with the dosage of LY294002, and the mRNA level of Rhob in RAW-GR(−) cells is about 2.3- and 3.2-fold of the control at 25 and 50 μM LY294002 respectively. The expression of RHOB protein was also further examined. The cells were treated with or without 50 μM LY294002, and the protein level was analyzed by western blot. Figure 7B shows that Rhob protein in RAW-GR(−) and RAW264.7 cells increased remarkably when compared with that of control when 50 μM LY294002 was added. These results demonstrated that PI3K/Akt signal was in the upstream of Rhob in these two cells and down-regulation of Rhob in RAW-GR(−) cells was resulted from the activation of PI3K/Akt pathway.

As shown in Fig. 3, we demonstrated that Dex increased the expression of Rhob in RAW264.7 cells at mRNA and protein levels. Does Dex also affect PI3K/Akt activity in RAW264.7 cells. Was the role of Dex on Rhob in the cells associated with Akt pathway? Therefore, we detected the effect of Dex on the protein level of p-Akt and Rhob in

Figure 4 RNA interference target Rhob gene knocks down Rhob expression in RAW264.7 cells. Twenty-four hours after transfection, RAW264.7 cells with negative control vector, pSilencer 2.1-U6-Rhob(1), or pSilencer 2.1-U6-Rhob(2), protein expression of RHOB in the cells was assayed by western blot analysis. Similar results were obtained from three independent experiments. The blots of RHOB in these two cells were quantified by Tanon software and normalized against β-actin. The normalized numbers from three independent experiments were compared. The values are expressed as the percentage of the level of RAW-control, as shown in the bar graph (X±s.d., n=3). **P<0.01 versus RAW264.7 cells transfected with negative control vector.

Figure 5 Increase in RHOB protein level or activity inhibits the proliferation of RAW264.7 cells, while decrease in RHOB protein level or activity promotes the cell proliferation. The level or activity of Rhob was increased by transfection of RAW264.7 cells with Rhob-wt (wild-type Rhob cDNA) or Rhob-V14 (constitutively active Rhob mutant), while the level or activity of Rhob was decreased by transfection with Rhob-RNAi (Rhob RNA interference plasmid) or Rhob-N19 (dominant negative mutant Rhob plasmid). Twenty-four hours after transfection, the cells were seeded and cultured in duplicate for 2 days in 6-well plate (2×10^5 cells/well) for (A) cytometry or (B) 24-well plate (3×10^4 cells/well) for MTT assay (X±s.d.). *P<0.05 versus cells transfected with blank vector (n=3).
RAW264.7 cells at the same time. A significant decrease in p-Akt protein expression was observed, following incubation of RAW264.7 cells with 10⁻⁷ M Dex for 4 h accompanied by an increase in Rhob and RU486, which could partially attenuate the down-regulation of p-Akt by Dex (Fig. 7C), indicating that activation of GR is required for p-Akt reduction. These results demonstrated that Dex inhibited the activity of Akt in RAW264.7 cells and the decrease in Akt activity might be resulted in the increase in Rhob expression of the cells.

Discussion

In our previous work, we found that the inhibition of GR expression in murine macrophage RAW-GR(−) cells by RNA interference resulted in significant enhancement of cell proliferation (Zhu et al. 2004). These results indicated that GR plays an important antiproliferative role in these macrophage cells. Although it is well known that GR mediates GC action by regulating the expression of target genes (Dondi et al. 2001, Zhu et al. 2004, Bladh et al. 2005), but a few target genes have been known to mediate the antiproliferative effect of GC until now.

Our other previous work found that Rhob could be induced by GC/GR and it at least partially mediated the antiproliferative effect of GC/GR in ovarian cancer HO-8910 cell lines (Chen et al. 2006). In this study, we found that GC also induced the expression of Rhob at both mRNA and protein levels in RAW264.7 cells and activation of GR is required for Rhob induction. The levels of Rhob at both mRNA and protein markedly decreased in RAW-GR(−) and RAW264.7 cells transiently transfected with GR RNA interference vector. Ectopic expression or constructive activation of Rhob by transfection with Rhob-wt or Rhob-V14 obviously inhibited the proliferation of RAW-GR(−) cell. Furthermore,
inhibition of the expression or activity of Rhob by transfection with Rhob-RNAi or Rhob-N19 resulted in a significant increase in cell proliferation of parental RAW264.7 cells, while increase in the expression or activity of Rhob by transfection with Rhob-wt or Rhob-V14 inhibited the proliferation. These results demonstrated that Rhob negatively regulated the proliferation of RAW264.7 cells and down-regulation of Rhob expression was associated with increased proliferation in RAW-GR(−) cell. It needs to be mentioned that Rhob expression and the proliferation of RAW-GR(−) cells showed no significant difference between culture in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 10% charcoal-stripped serum (deprived of GC). The data indicated that the presence or absence of GC had no effect on Rhob expression when knock down of GR in RAW-GR(−) cells, while GC promoted the expression of Rhob remarkably in RAW264.7 cells through GR mediation. Therefore, we speculated that Rhob expression might be mainly regulated by GR in an agonist-independent way.

How GR up-regulates the expression of Rhob remains unknown. It is well known that GR up-regulates gene transcription usually through direct binding to GRE in the promoter region of target genes, where it serves to recruit other proteins, such as coactivators involved in transcription (Zhu et al. 2004, Bladh et al. 2005). However, our previous work demonstrated that the activity of a luciferase reporter gene containing a ∼1.9 kb (−1756/+111) fragment of the promoter sequence of human Rhob gene was not induced by GC/GK in ovarian cancer HO-8910 cells, indicating that there was no functional GRE in this promoter region (−1765/+111; Chen et al. 2006). We also analyzed a 5 kb fragment of the promoter sequence upstream of the transcriptional start site of the Rhob gene, and found no consensus GRE (Chen et al. 2006). In recent years, evidence has emerged that besides its role in directly regulating gene expression, GR could modulate the activity of several cytoplasmic protein kinases, such as Akt (Leis et al. 2004, Chrysis et al. 2005, Nuutinen et al. 2006), MAPK3/1, and MAPK14 (Miller et al. 2005, Qin et al. 2005), to play its important roles in regulating cell proliferation, differentiation, and apoptosis. Leis et al. (2004) reported that GR inhibited PI3K and Akt activity, which constituted a major mechanism underlying the antitumor effect of GC in skin. Reports also showed that GC/GR induces apoptosis in proliferative chondrocytes and a human follicular lymphoma cell line through suppression of the Akt-PI3K signaling pathway (Chrysis et al. 2005, Nuutinen et al. 2006). In this study, we also found that except for the down-regulation of Rhob, the activity of Akt was enhanced in RAW-GR(−) cells. Furthermore, Dex decreased the expression of p-Akt accompanied with an increase in Rhob. Therefore, it is interesting to know whether the increased proliferation of RAW-GR(−) cells is related to the down-regulation of Rhob expression from activation of Akt. Treatment of RAW-GR(−) and RAW-control cells with 25 μM LY294002, a specific inhibitor of PI3K/Akt pathway, resulted in a more obvious growth repression and a more obvious up-regulation of Rhob expression in RAW-GR(−) cells than that in RAW-control cells, though the effect could be seen in both the two cells. These results indicated that inhibition of GR expression in RAW-GR(−) cells leads to activation of Akt, and the latter subsequently down-regulates the expression of Rhob, which results in the faster growth of the cells. Jiang et al. (2004a,b) also reported that activated Akt by EGFR-Ras signaling suppresses Rhob promoter activity by a PI3K/Akt-dependent mechanism.

It has been reported that Akt regulated cell growth progress by controlling the expression and activity of multiple cell cycle regulatory proteins, such as cyclin D1, cyclin E, CDK2, CDK4, and cyclin-dependent kinase inhibitors CDKN1B and CDKN1A (Shukla & Gupta 2007, Lee et al. 2008, Seo et al. 2008). Wu et al. (2008) reported that PRKCA, a regulator of cell proliferation, was highly expressed in the poorly differentiated hepatocellular carcinoma cell lines and the reduction in PRKCA expression resulted in a decrease in the growth rate and the level of cyclin D1 in these cells. In our previous study, we demonstrated that increased proliferation of RAW-GR(−) cells was associated with an increase in PRKCA and decrease in CDKN1B (Zhu et al. 2004) and with an increase in CDK2, cyclin D1, and cyclin B1 (unpublished). These results suggest that the role of GR on cell cycle regulatory proteins may be through regulating the expression of Akt and PRKCA in RAW264.7 cells, but it needs further study.

In summary, our experiments demonstrate that Rhob plays an important role in the antiproliferative effect of GR on RAW264.7 cells by GR→Akt→Rhob pathway and Rhob negatively regulated the proliferation of RAW264.7 cells.

Declarations of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 30300128).

Acknowledgements

We gratefully thank Dr G.C. Prendergast for providing the constitutively active Rhob-G14V, dominant negative Rhob-T19N, and wild-type Rhob cDNA plasmids.

References

Role of RhoB in the antiproliferative effect of GR · X WANG, Y CHEN and others


Pagniello KB, Bols NC & Lee LE 2002 Effect of corticosteroids on viability and proliferation of the rainbow trout monocye/macrophage cell line, RTS11. *Fish and Shellfish Immunology* 13 199–214.


Received in final form 14 September 2008
Accepted 26 September 2008
Made available online as an Accepted Preprint 7 October 2008

www.endocrinology-journals.org

Journal of Endocrinology (2009) 200, 35–43

Downloaded from Bioscientifica.com at 07/29/2019 06:52:41AM via free access